NCT03503968 is a Phase 1, PHASE2 clinical trial of MDG1011 in Safety, sponsored by Medigene AG.

Who is sponsoring NCT03503968?

NCT03503968 is sponsored by Medigene AG.

What drugs are being tested in NCT03503968?

Interventions in NCT03503968: MDG1011, Investigator Choice therapy.

What condition does NCT03503968 study?

NCT03503968 studies Safety, Tolerability, Feasibility, Treatment Efficacy.

Is NCT03503968 still recruiting?

NCT03503968 is currently terminated. Last updated 15 February 2023.

Last reviewed 2023-02-15 · How we verify

NCT03503968

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms

Terminated Phase 1, PHASE2 Last updated 15 February 2023

What this trial tests

Phase 1, PHASE2 trial testing MDG1011 in Safety in 9 participants. Terminated before completion.

Timeline

27 March 2018

Primary endpoint
28 June 2022

15 July 2022

Quick facts

Lead sponsor	Medigene AG
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	27 March 2018
Primary completion	28 June 2022
Estimated completion	15 July 2022
Sites	9 locations across Germany

Drugs / interventions tested

MDG1011 — full drug profile →
Investigator Choice therapy

Conditions studied

Safety — all drugs for Safety →
Tolerability — all drugs for Tolerability →
Feasibility — all drugs for Feasibility →
Treatment Efficacy — all drugs for Treatment Efficacy →

Sponsor

Medigene AG — full company profile →

Who can join

18 and older, any sex, with Safety or Tolerability. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicentre, non-randomized, open-label, Phase I/II clinical trial of MDG1011, an investigational medicinal product (IMP), consisting of patient-derived autologous T cells, persistently transduced with a Preferentially Expressed Antigen in Melanoma (PRAME)-specific human leukocyte antigen (HLA)-A\*02:01-restricted T cell receptor (TCR).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical cancer immunotherapy: Current progress and prospects.
Liu C, Yang M, Zhang D, Chen M, et al · · 2022 · cited 147× · PMID 36304470 · DOI 10.3389/fimmu.2022.961805
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome.
Klebanoff CA, Chandran SS, Baker BM, Quezada SA, et al · · 2023 · cited 132× · PMID 37891435 · DOI 10.1038/s41573-023-00809-z
The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review.
Zhang J, Wang L. · · 2019 · cited 115× · PMID 30798772 · DOI 10.1177/1533033819831068
Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.
Zhao Q, Jiang Y, Xiang S, Kaboli PJ, et al · · 2021 · cited 97× · PMID 33859650 · DOI 10.3389/fimmu.2021.658753
Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
Al-Khadairi G, Decock J. · · 2019 · cited 85× · PMID 31311081 · DOI 10.3390/cancers11070984
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML).
Hofmann S, Schubert ML, Wang L, He B, et al · · 2019 · cited 84× · PMID 30736352 · DOI 10.3390/jcm8020200
Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia.
Restelli C, Ruella M, Paruzzo L, Tarella C, et al · · 2024 · cited 36× · PMID 38904305 · DOI 10.1158/2643-3230.bcd-23-0202
T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies.
Biernacki MA, Brault M, Bleakley M. · · 2019 · cited 34× · PMID 31135525 · DOI 10.1097/ppo.0000000000000378

Verify or expand the search:

Other recruiting trials for Safety

Currently open trials in the same condition.

NCT06818994 — Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced · Phase 1 · recruiting
NCT07286656 — A Study of GensSci098 in Subjects With Graves' Disease · Phase 1 · recruiting
NCT06760208 — A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market · recruiting
NCT07157215 — An International Survey on the Use of NIV Outside the ICU · recruiting
NCT06976229 — Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase · Phase 1 · recruiting

Other Medigene AG trials

Trials by the same sponsor.

NCT06748872 — EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03503968 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medigene AG
Last refreshed: 15 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03503968.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing